-11%

est. 2Y upside i

HealthcareSeries A

Rank

#2563

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

Peptone's pre-revenue status and stale 2022 valuation make equity highly speculative.

Last updated: July 19, 2026

Bull (15%)+140%

Pipeline advances to clinical trials, leading to Series B at 3x current valuation ($265M), but 20% dilution from new round results in ~140% net upside for employees.

Base (55%)-4%

Modest progress, valuation flat at $88.5M; a $15M bridge round at same price causes 20% dilution, reducing per-share value by 4%.

Bear (30%)-100%

Key program fails preclinical, company unable to raise, common stock worthless given $42.5M preference stack.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

48%

Total funding of $42.5M vs valuation $88.5M results in a 48% preference overhang, meaning common stock only recovers value above $42.5M.

Dilution Risk

high

With $42.5M raised and likely high burn rate, a Series B or bridge round may dilute existing shareholders by 15-25%.

Secondary Liquidity

none

No secondary market observed for Peptone shares.

View all 2 open roles at Peptone →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Peptone's data — designed to show you've done your homework.

  • 1

    “How does Peptone's platform specifically de-risk the preclinical phase for IDP targets compared to competitors?”

  • 2

    “What is the projected cash runway and plans for the next funding round?”

  • 3

    “Given the long timeline to liquidity, how do you value equity in a pre-revenue biotech vs a cash bonus?”

Community

Valuation Sentiment

Our model estimates -11% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.